Verteporfin therapy in combination with triamcinolone: Published studies investigating a potential synergistic effect

Current Medical Research and Opinion

Volumn 21, Issue 5, 2005, Pages 705-713

  Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Triamcinolone acetonide; Verteporfin therapy

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PLACEBO; TRIAMCINOLONE ACETONIDE;

BACKACHE; CATARACT; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; HUMAN; INJECTION SITE REACTION; INTRAOCULAR PRESSURE ABNORMALITY; MEDLINE; META ANALYSIS; OUTCOMES RESEARCH; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER; VISUAL IMPAIRMENT;

CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MACULAR DEGENERATION; PHOTOSENSITIZING AGENTS; PORPHYRINS; TRIAMCINOLONE; VISUAL ACUITY;

EID: 18844420246     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X43659     Document Type: Review

References (91)

1. Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology 2004;111:53-61
2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85
3. Dimitrov PN, Mukesh BN, McCarty CA, Taylor HR. Five-year incidence of bilateral cause-specific visual impairment in the Melbourne Visual Impairment Project. Invest Ophthalmol Vis Sci 2003;44:5075-81
4. Foran S, Wang JJ, Mitchell P. Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003;10:215-25
5. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
6. Sackett CS, Schenning S. The age-related eye disease study: the results of the clinical trial. Insight 2002;27:5-7
7. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol 2001;119:1417-36
8. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study report Number 6. Am J Ophthalmol 2001;132:668-81
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-14
10. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-9
11. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-9
12. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: a case-control study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study report Number 3. Ophthalmology 2000;107:2224-32
13. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol 2004;15:181-3
14. McGwin Jr G, Chapman V, Owsley C. Visual risk factors for driving difficulty among older drivers. Accid Anal Prev 2000;32:735-44
15. Wood JM. Age and visual impairment decrease driving performance as measured on a closed-road circuit. Hum Factors 2002;44:482-94
16. Owsley C, McGwin Jr G, Sloane ME, Stalvey BT, Wells J. Timed instrumental activities of daily living tasks: relationship to visual function in older adults. Optom Vis Sci 2001;78:350-9
17. Rubin GS, Roche KB, Prasada-Rao P, Fried LP. Visual impairment and disability in older adults. Optom Vis Sci 1994;71:750-60
18. Hassan SE, Lovie-Kitchin JE, Woods RL. Vision and mobility performance of subjects with age-related macular degeneration. Optom Vis Sci 2002;79:697-707
19. Kuyk T, Elliott JL. Visual factors and mobility in persons with age-related macular degeneration. J Rehabil Res Dev 1999;36:303-12
20. Klein BE, Moss SE, Kein R, Lee KE, Cruickshanks KJ. Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam Eye Study. Ophthalmology 2003;110:644-50
21. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005;25:119-34
22. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207
23. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials - TAP report No. 7. Arch Ophthalmol [in press]
24. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report No. 5. Arch Ophthalmol 2002;120:1307-314
25. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin In Photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60
26. Kaiser PK, TAP Study Group. Five-year results of verteporfin therapy for subfoveal CNV due to AMD: third year of an open-label extension of the TAP investigation. Invest Ophthalmol Vis Sci 2003;44:E-Abstract 1099
27. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50
28. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-73
29. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-8
30. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 2005;19:163-70
31. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25
32. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-4
33. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefe's Arch Clin Exp Ophthalmol 2002;240:42-8
34. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 2001;411:231-43
35. Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986;119:1768-75
36. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000;121:458-65
37. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43:3125-30
38. Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986;119:62-9
39. Umland SP, Nahrebne DK, Razac S, et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997; 100:511-9
40. Bhattacherjee P, Williams RN, Eakins KE. A comparison of the ocular anti-inflammatory activity of steroidal and nonsteroidal compounds in the rat. Invest Ophthalmol Vis Sci 1983;24:1143-6
41. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404
42. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-104
43. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental preretinal neovascularization. Graefe's Arch Clin Exp Ophthalmol 1993;231:34-40
44. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan Jr E. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992;110:1155-9
45. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-22
46. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust New Zealand J Ophthalmol 1998;26:277-81
47. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust New Zealand J Ophthalmol 1995;23:293-8
48. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-9
49. Jonas JB, Degenring R, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for exudative AMD. Presented at the American Academy of Ophthalmology and European Society of Ophthalmology 2004 Joint Meeting; 23-26 October 2004: New Orleans, LA, USA. http://www.aao.org [accessed 11 March 2005]
50. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122:336-40
51. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-90
52. Peck RE, Rhee DJ, Liu M, et al. Prevalence of intraocular pressure alterations following intravitreal triamcinolone acetonide injections. Presented at the American Academy of Ophthalmology and European Society of Ophthalmology 2004 Joint Meeting; 23-26 October 2004: New Orleans, LA, USA. http://www.aao. org [accessed 11 March 2005]
53. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6
54. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-91
55. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:19S-214
56. Schmidt-Erfurth U, Hasan T, Schomacker K, Flotte T, Birngruber R. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 1995;17:178-88
57. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953-61
58. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefe's Arch Clin Exp Ophthalmol 2002;240:748-57
59. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002;134:566-76
60. Eter N, Bindewald A, Roth F, Holz FG. OCT in age-related macular degeneration. Findings, usage in clinical routine, and assessment of treatment outcome. Ophthalmologe 2004;101:794-803
61. Visudyne in Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial. Arch Ophthalmol [in press]
62. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration - TAP and VIP report No. 1. Am J Ophthalmol 2003;136:407-18
63. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study report No. 4. Retina 2004;24:1-12
64. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Acute severe visual acuity decrease after photodynamic therapy with Verteporfin: case reports from randomized clinical trials - TAP and VIP report No. 3. Am J Ophthalmol 2004;137:683-96
65. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18
66. Centers for Medicare and Medicaid Services (CMS) - US Dept of Health and Human Services. National coverage analysis (NCA). Ocular photodynamic therapy with verteporfin for macular degeneration (#CAG-00066R3). www.cms.hhs.gov [accessed 11 March 2005]
67. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003;88:1772-9
68. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1991;112:647-56
69. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefe's Arch Clin Exp Ophthalmol 1994;232:325-9
70. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3. Arch Ophthalmol 2002;120:1443-54
71. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830-41
72. Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefe's Arch Clin Exp Ophthalmol 1997;235:159-67
73. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-34
74. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Trans-differentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-68
75. Cui JZ, Kimura H, Spee C, Thumann G, Hinton DR, Ryan SJ. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefe's Arch Clin Exp Ophthalmol 2000;238:326-33
76. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-44
77. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8
78. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001;188:253-63
79. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80
80. Li R, Nelkenbrecher K, McGrogan M, et al. Comparison of PDT with verteporfin and intravitreal triamcinolone acetonide injection in a rat model of laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci 2004;45:E-Abstract 472
81. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999;117:1329-45
82. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-7
83. Moshfeghi A, Puliafito C, Rosenfeld P. Combination verteporfin therapy and intravitreal triamcinolone in neovascular age-related macular degeneration. Presented at the 2004 Meeting of the Retina Society; 30 September-3 October 2004: Baltimore, MD, USA
84. Augustin AJ, Schmidt-Erfurth U. PDT and triamcinolone for the treatment of occult CNV in AMD. Presented at the 27th Annual Macula Society Meeting; 26 February-1 March 2004: Las Vegas, NV, USA
85. El Matri L, Baklouti K, Mghaieth F, et al. Photodynamic therapy and intravitreal triamcinolone for exsudative [sic] age related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:E-Abstract 3162
86. Johnson RN, Yang S, McDonald HR, Ai E, Jumper JM. Combined photodynamic therapy and intravitreal triamcinolone acetonide for AMD. Presented at the American Academy of Ophthalmology and European Society of Ophthalmology 2004 Joint Meeting; 23-26 October 2004: New Orleans, LA, USA. http://www.aao.org [accessed 11 March 2005]
87. Roth DB, Walsman S, Modi A, et al. Intravitreal triamcinolone combined with photodynamic therapy for exudative macular degeneration. Presented at the American Academy of Ophthalmology and European Society of Ophthalmology 2004 Joint Meeting; 23-26 October 2004: New Orleans, LA, USA. http://www.aao.org [accessed 11 March 2005]
88. Bhavsar AR. Combined verteporfin therapy and intravitreal triamcinolone in the treatment of minimally classic subfoveal CNV with or without RAP lesions. Presented at the American Academy of Ophthalmology and European Society of Ophthalmology 2004 Joint Meeting; 23-26 October 2004: New Orleans, LA, USA. http://wwvv.aao.org [accessed 11 March 2005]
89. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone for juxtafoveal and extrafoveal choroidal neovascularization. Presented at the American Academy of Ophthalmology and European Society of Ophthalmology 2004 Joint Meeting; 23-26 October 2004: New Orleans, LA, USA. http://www.aao.org [accessed 11 March 2005]
90. Rogers DL, Danis RP, Gao H. Photodynamic therapy with verteporfin combined with intravitreal triamcinolone acetonide for the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci 2004;45:E-Abstract 3157
91. Bhavsar AR. Combined intravitreal triamcinolone and PDT in the treatment of minimally classic subfoveal CNV with or without RAP lesions. Presented at the American Society of Retina Specialists 2004 Annual Meeting; 16-20 August 2004: San Diego, CA, USA